Featuring perspectives from Dr Floor J Backes, including the following topics:
- Available data with and clinical investigator perspectives on trastuzumab deruxtecan for the management of gynecologic cancers (0:00)
- Patient-specific factors guiding treatment selection and sequencing for ovarian cancer (OC) (6:05)
- Management of adverse events associated with PARP inhibitor maintenance therapy for OC; safety concerns in the later-line setting (15:00)
- Management approaches for ocular toxicity and other adverse events associated with mirvetuximab soravtansine (20:28)
- Current role of upifitamab rilsodotin in the management of OC and available data with tumor treating fields (24:38)
- Investigator perspectives on the current chemotherapy shortage; recently published Phase III data with chemoimmunotherapy for endometrial cancer (29:11)
- Tisotumab vedotin for cervical cancer (36:34)
CME information and select publications
Research To Practice | Oncology Videos